Want your patients
to be more like Max?

Prescribe an inhaler that can deliver in the real world:

  • Used correctly by 93% of people after reading the PIL*1
  • Consistent dose delivery:**
    • At flow rates of 30–90L/min2,3
    • When held at +/-90 degrees from vertical3
    • At temperatures from -20°C to 40°C3
  • Licensed for use as maintenance and reliever therapy (MART) in asthma†4

About DuoResp Spiromax

  • DuoResp Spiromax contains budesonide and formoterol1
  • Dry powder inhaler
  • Licenced for asthma and COPD4

PIL, patient information leaflet.

*Correct usage data after reading PIL for Turbohaler® and Easyhaler® were 76.7% and 58.3% respectively (p<0.001, for both comparisons) n=120 for all groups.1 Patients are advised to read the PIL carefully and follow the instructions for use as detailed in the leaflet.

**Dose delivery study using low, middle and high strength DuoResp Spiromax. Dose consistency was measured over inhaler life. Low dose was included in the study but is not licensed in the UK.3

†For 160/4.5mcg strength only.4

‡DuoResp Spiromax is licensed for use in adults 18 years of age and older only.4

§The label on DuoResp Spiromax indicates delivered dose.

  1. Sandler N et al. BMJ Open Resp Res 2016; 3: e000119.
  2. Chrystyn H et al. Int J Pharm 2015; 491: 268–276.
  3. Canonica G et al. J Aerosol Med Pulm Drug Deliv 2015; 28(5): 309–319.
  4. DuoResp Spiromax Summary of Product Characteristics.